A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis

Journal of Theoretical Biology

Volumn 227, Issue 2, 2004, Pages 219-228

  Agius, Lawrence M ^a,b  

^a UNIVERSITY OF MALTA MEDICAL SCHOOL   (Malta)

^b NONE   (United Kingdom)

Author keywords

Epithelial cell; Immunoregulation; Inflammatory bowel disease; Pattern response

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; IMMUNOMODULATING AGENT; INFLIXIMAB; LIPOPOLYSACCHARIDE; NATALIZUMAB; NITRIC OXIDE; OXYGEN RADICAL; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

BIOLOGY; DIGESTIVE SYSTEM; DISEASE;

ANTIGEN PRESENTATION; ANTIGENICITY; CROHN DISEASE; DISEASE MARKER; DISEASE PREDISPOSITION; ENTERITIS; EPITHELIUM CELL; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INTESTINE MUCOSA; MICROFLORA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

EID: 1442335468     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtbi.2003.11.002     Document Type: Article

References (63)

1. Abdo A.et al. Clinical and histological predictors of response to medical therapy in collagenous colitis. Am. J. Gastroenterol. 97(5):2002;1164-1168.
2. Abreu M.T. The pathogenesis of inflammatory bowel disease. translational implications for clinicians Curr. Gastroenterol. Rep. 4(6):2002;481-489.
3. Agyckum S., Church A., Sohail M., Drausz T.et al. Expression of lymphotoxin-beta (LT-beta) in chronic inflammatory conditions. J. Pathol. 199(1):2003;115-121.
4. Allez M., Brimnes J., Dotan I., Mayer L. Expression of CD+8 T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology. 123(5):2002;1516-1526.
5. Araki Y., Andoh A., Fujiyama Y., Itoh A., Bamba T. In vitro alterations in fecal short chain fatty acids and organic anions induced by the destruction of intestinal microflora under hypotonic and aerobic conditions. Int. J. Mol. Med. 9(6):2002;627-631.
6. Ardizzone S., Porre G.B. Inflammatory bowel disease. new insights into pathogenesis and treatment J. Intern. Med. 252(6):2002;475-496.
7. Autischbach F., Giese T., Gassler N., Sido B.et al. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 441(5):2002;500-513.
8. Ayata G., Ithamukkala S., Sapp H., Shaz B.H., Brien T.P.et al. Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis. Am. J. Surg. Pathol. 26(11):2002;1414-1423.
9. Banks C., Bateman A., Payne R., Johnson P., Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199(1):2003;28-35.
10. Basset C., Holton J. Inflammatory bowel disease. is the intestine a Trojan horse? Sci. Progr. 85(Pt1):2002;33-56.
11. Befrits R., Ljung T., Jaramillo E., Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease. a follow-up study Dis. Colon Rectum. 45(5):2002;615-620.
12. Bernstein C.N., EadeuJ, Steinhart A.H., Munkholm P., Gordon P.H. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm. Bowel Dis. 8(5):2002;356-361.
13. Biancone L., Monteleone I., Del Vecchio Blanco G., Bavassori P., Pallone F. Resident bacterial flora and immune system. Dig. Liver Dis. 34(Suppl. 2):2002;S37-S43.
14. Brant S.R., Picco M.F., Achkar J.P., Baylass T.M.et al. Defining complex contributions of NOD2/CARD15 gene mutations, age of onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. 9(5):2003;281-289.
15. Bouma G., Strober W. The immunoloigcal and genetic basis of inflammatory bowel disease. Natl. Rev. Immunol. 3(7):2003;531-533.
16. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development. twenty-six cases reported to the food and drug administration Arthritis Rheumatol. 46(12):2002;3151-3158.
17. Cabarrocas J., Savudge T.Cm., Kubkay R.S. Role of enteric glial cells in inflammatory bowel disease. Glia. 41(1):2003;81-93.
18. Conrad K., Schmechta H., Klafki A., Lobeck G., Uhlig H.H., Gerdi S., Henker J. Serological differentiation of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 14(2):2002;129-135.
19. Cosmes J., Carbonnel F., Beaugeria L., Blaiu A., Reijasse D., Gendre J.P. Effects of appendicectomy on the course of ulcerative colitis. Gut. 51(6):2002;803-807.
20. Dijkstra G., Moshage H., Jausen P.L. Blockade of NF-kappaB activation and donation of nitric oxide. new treatment options in inflammatory bowel disease? Scand. J. Gastroenterol. 236(Suppl.):2002;37-41.
21. DiLeo V., Yang P.C., Beriu M.C., Perdue M.H. Factors regulating the effect of IL-4 on intestinal epithelial barrier function. Int. Arch. Allergy Immunol. 129(3):2002;219-227.
22. Faust D., Raschke K., Hormann S., Milovic V., Stein J. Regulation of alpha1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clin. Exp. Immunol. 128(2):2002;279-284.
23. Freeman H.J. Tabulation of myeloid, lymphoid and intestinal malignancies in Crohn's disease. Can. J. Gastroenterol. 16(11):2002;779-784.
24. Fujino S., Andoln A., Bamba S., Ogawa A.et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52(1):2003;65-70.
25. Gasche C., Scholmerich J., Brynskow J., D'Haems G.et al. A simple classification of Crohn's disease. report of the working party for the world Congresss of gastroenterology, Vienna 1999 Inflamm. Bowel Dis. 6(1):2000;8-15.
26. Gewirtz A.T., Liu Y., Sitaraman S.V., Madara J.L. Intestinal epithelial pathobiology. past, present and future Best Pract. Res. Clin. Gastroenterol. 16(6):2002;851-867.
27. Glas J., Torok H.P., Vilsinaier F., Herbinger K.H., Hollscher M., Folwaczny C. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first degree relatives. potential clinical value Digestion. 66(3):2002;173-177.
28. Harlan J.M., Winn R.K. Leukocyte-endothelial interactions. clinical trials of anti-adhesion therapy Crit. Care Med. 30(5 Suppl.):2002;S214-S219.
29. Holtmeier W., Hennemann A., May E., Duchmann R., Caspary W.F. T cell receptor delta repertoire in inflamed and noninflamed colon of patients with IBD analyzed by CDR3 spectratyping. Am. J. Physiol.: Gastrointest. Liver Physiol. 282(6):2002;G1024-G1034.
30. Judge T.A., Lewis J.D., Lichtenstein G.R. Colonic dysplasia and cancer in inflammatory bowel disease. Gastrointest. Endosc. Clin. North Am. 12(3):2002;495-523.
31. Kader H.A., Berman W.F., Al-Seraihy A.S., Wara R.E., Ulshen M.H., Treen W.R. Prevalence of factor V9169A (Leiden), Prothrombin 920210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 35(5):2002;629-635.
32. Khan K., Schwarzenberg S.J., Sharp H., Greenwood D., Weisdorf-Schindele S. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm. Bowel Dis. 8(5):2002;325-329.
33. Koutoyiannis D., Boulougouris G., Manoloukos M., Armaka M.et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 196(12):2002;1563-1574.
34. Kruidenier L., Verspaget H.W. Oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment. Pharmacol. Ther. 16(12):2002;1997-2015.
35. Kwon J.H., Keates S., Bassani L., Mayer L.F., Keates A.C. Colonic epithelial cells are a major site of macrophage inflammatory protein 3 alpha (MIP-3 alpha) production in normal colon and inflammatory bowel disease. Gut. 51(6):2002;818-826.
36. Mahler M., Leiter E.H. Genetic and environmental context determines the course of colitis developing in IL-10 deficient mice. Inflamm. Bowel Dis. 8(5):2002;347-355.
37. Markowitz J., Graucher K., Kohn N., Dawn F. Immunomodulatory therapy for pediatric inflammatory bowel disease. changing patterns of use 1990-2000 Am. J. Gastroenterol. 97(4):2002;928-932.
38. Matsuzawa J., Sugimura K., Matsuda Y., Takazoe M.et al. Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population. Gut. 52(1):2003;75-78.
39. Montogomery S.M., Lambe M., Wakefield A.J., Pounder R.E., Ekbom A. Siblings and the riskof inflammatory bowel disease. Scand. Gastroenterol. 37(11):2002;1301-1308.
40. Naser S.A., Shafran I., Schwartz D., El-Zaatari F., Biggerstaff J. In situ identification of mycobacteria in Crohn's disease patient tissue using confocal scanning laser microscopy. Mol. Cell Probes. 16(1):2002;41-48.
41. Oshitani N., Hato F., Kitagawa S., Maeda K., Higuchi K., Matsumoto T., Arakawa T. Analysis of intestinal HLA-DR bound peptides and dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease. Int. J. Mol. Med. 11(1):2003;99-104.
42. Patel B., Schutte R., Sprus P., Doyle J., Jewel L., Fedorak R.N. Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. Inflamm. Bowel Dis. 8(5):2002;340-346.
43. Pauleau A.L., Murray P.J. The role of nod2 in the response of macrophages to toll-like receptor antagonists. Mol. Cell. Biol. 23(21):2003;7531-7539.
44. Podolsky D.K. The current future understanding of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 16(6):2002;933-943.
45. Radford-Smith G.L., Edwards J.E., Purdie D.M., Pandeya N.et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut. 51(6):2002;808-813.
46. Ruemmele F.M., Beaulieu J.F., Dionue S., Levy E., Seidman E.G., Cerf-Bensussan N., Lentze M.J. Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumor necrosis factor alpha. Gut. 51(6):2002;842-848.
47. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J. Gastroenterol. Hepatol. 17(Suppl. 1):2002;176-185.
48. Sandborn W.J., Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology. 122(6):2002;1592-1608.
49. Sasaki M., Jordan P., Joh T., Itoh M., Jenkins M., Pavlick K., Minagar A., Alexander S.J. Melatonin reduces TNF-A induced expression of MAdCAM-1 via inhibition of NF-kB. BMC Gastroenterol. 2(1):2002;9.
50. Sawai T., Lampman R., Hua Y., Segura B., Drongowski R.A., Coran A.G., Harmon C.M. Lysophosphatidylcholine alters enterocyte monolayer permeability via a protein kinase C/Ca(2+) mechanism. Pediatr. Surg. Int. 18(7):2002;591-594.
51. Shanahan F. The host-microbe interface within the gut. Best Pract. Res. Clin. Gastroenterol. 16(6):2002;915-931.
52. Shaw S.H., Hampe J., White R., Mathew C.G.et al. Stratification by CARD15 variant genotype in a genome-wide search for inflammatory bowel disease susceptibility loci. Hum. Genet. 113(6):2003;514-521.
53. Sivakumar P.V.et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis. blocking interleukin 18 attenuates intestinal damage Gut. 50(6):2002;812-820.
54. Stallmach A., Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm. Bowel Dis. 8(3):2002;213-218.
55. Stevceva L. Cytokines and their antagonists as therapeutic agents. Curr. Med. Chem. 9(24):2002;2201-2207.
56. Takesue T., Ohge H., Uemura K., Imamura Y.et al. Bacterial translocation in patients with Crohn's disease undergoing surgery. Dis. Colon Rectum. 45(12):2002;1665-1671.
57. Togawa J., Nagase H., Tanaka K., Inamori M.et al. Oral administration of lactoferrin reduces colitis and rate via modulation of the immune system and correction of cytokine imbalance. J. Gastroenterol. Hepatol. 17(12):2002;1291-1298.
58. Ullman T.A. Cancer in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 5(3):2002;163-171.
59. Van Den Brande, J.M., Peppelenbosch, M.P., Van Deveater, S.J., 2002. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann. N. Y. Acad. Sci. L973, 166-180.
60. Van Heel D.A., Udalova I.A., De Silva A.P., McGovern D.P., Kinouchi Y., Hull J., Lench N.J., Cardon L.R., Carey A.H., Jewell D.P., Kwiatkowski D. Inflammatory bowel disease is associated with a tnf polymorphism that affects an interaction between the OCT1 and NF-kappaB transcription factors. Hum. Mol. Genet. 11(11):2002;1281-1289.
61. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S. p38 Mitogen-activated protein kinase is activated and linked in TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 168(10):2002;5342-5351.
62. Wang X., Hone D.M., Haddad A., Shata M.T.et al. M cell DNA vaccination for CTL immunity to HIV. J. Immunol. 171(9):2003;4717-4725.
63. Yukawa M., Iizuka M., Horie Y., Yoneyama K., Shirasaka T., Itou H., Komatsu M., Fukushima T., Watanabe S. Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. Int. J. Colorectal Dis. 17(2):2002;70-76.